Arkolith/Insider Trading/APRE/Form 4

Duey Marc

DirectorAprea Therapeutics, Inc. (APRE) · full profile →Form 4 · filed Aug 24, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 23, 2023Grant(A)500—$0209K
Aug 23, 2022Conversion(C)12K—$0602
Aug 23, 2022Conversion(C)4.0M—$04.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 23, 2023Grant(A)2K—$02K
Aug 23, 2022Conversion(C)401K—$00
Aug 23, 2022Conversion(C)1K—$00

Transaction Codes

A
Grant / award
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-095017) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML